Exclusive: Biogen prices hemophilia drug on par with older therapies

[Reuters] – The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month w more

View todays social media effects on BIIB

View the latest stocks trending across Twitter. Click to view dashboard

See who Biogen is hiring next, click here to view